INNOVENT BIO's stock surged 6.05% during morning trading, reflecting strong investor confidence following the release of the company's annual financial results.
The company reported total revenue of RMB 13.0415 billion, representing a year-on-year increase of 38.4%. Notably, INNOVENT BIO achieved its first full-year profit, with IFRS net profit reaching RMB 814 million, a significant turnaround from a loss of RMB 94.63 million in the previous year.
Product revenue, a key driver of growth, rose 44.6% year-on-year to RMB 11.896 billion, bolstered by the company's leading position in oncology and the rapid expansion of its product portfolio. Non-IFRS net profit also saw a dramatic increase of 419.6% to RMB 1.723 billion, further underscoring the company's enhanced profitability.
Comments